Conmy Use In Pregnancy & Lactation

Use in Pregnancy: Teratogenic Effects: Terazosin was not teratogenic in either rats or rabbits when administered oral doses up to 280 to 60 times; respectively, the maximum recommended human dose. Fetal resorptions occurred in rats with 480 mg/kg/day, approximately 280 times to maximum recommended human dose. Increased fetal resorptions, decrease fetal weight and an increased number of supernumerary ribs were observed in offspring of rabbits dosed with 60 times the maximum recommended human dose. The finding (in both species) were most likely secondary to maternal toxicity. There are no adequate and well-controlled studies in pregnant women and the safety of terazosin in pregnancy has not been established. Terazosin hydrochloride is not recommended during pregnancy unless the potential benefit justifies the potential risk to the mother and fetus. Non-teratogenic Effects: In a peri- and post-natal development study in rats, significantly more pups died in the group dosed with 120 mg/kg/day (>75 times the maximum recommended human dose) then in the control group during the three week postpartum period.
Use in Lactation: It is not known whether terazosin is excreted in breast milk. Because many drugs are excreted in milk, caution should exercised when terazosin is administered to a nursing woman.